Investors

Investors

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

Latest Press Releases

Date Title and Summary
Toggle Summary New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Clinical Outcomes in Patients with High Recurrence Score® Results Presented Today in Oral Session at ESMO 2019 Congress   With Fourth Peer-Reviewed Publication, TAILORx Continues to Elevate Oncotype DX® Test to a New Global Standard     REDWOOD CITY, Calif. , Sept.
Toggle Summary New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
- Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy - Oncotype DX® test recommended based on prospective landmark TAILORx and German PlanB studies,
Toggle Summary Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
Delivered $114.1M in Revenue and Growth of 19.4% in the Second Quarter Reported $16.0M in Profit and EPS of $0.42 Per Share on a Diluted Basis Raises Full-Year 2019 Revenue and Net Income Guidance Earnings Call and Webcast Previously Scheduled for Thursday, August 1 Will Now Occur Today Monday,
Toggle Summary Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-class commercial, research, development and clinical organization, with enhanced scale and scope in cancer diagnostics Global infrastructure

DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.